Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | Nasdaq Biotechnology |
| Investment focus | Actions, États-Unis, Santé |
| Fund size | EUR 790 m |
| Total expense ratio | 0,35% p.a. |
| Replication | Physical (Optimized sampling) |
| Legal structure | ETF |
| Strategy risk | Long-only |
| Sustainability | Non |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in EUR) | 22,96% |
| Inception/ Listing Date | 19 octobre 2017 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Irlande |
| Fund Provider | iShares |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Fund Services (Ireland) Limited |
| Investment Advisor | |
| Custodian Bank | State Street Custodial Services (Ireland) Limited |
| Revision Company | Deloitte |
| Fiscal Year End | 31 mai |
| Swiss representative | BlackRock Asset Management Schweiz AG |
| Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
| Germany | 30% d’exonération partielle |
| Switzerland | ESTV Reporting |
| Austria | Meldefonds |
| UK | UK Reporting |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
| Securities lending | Yes |
| Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
| Amgen | 7.80% |
| Gilead Sciences | 7.24% |
| Vertex Pharmaceuticals | 7.20% |
| Regeneron Pharmaceuticals | 6.33% |
| Alnylam Pharmaceuticals | 4.61% |
| AstraZeneca PLC ADR | 3.77% |
| Insmed | 3.45% |
| argenx | 2.19% |
| Biogen | 2.10% |
| United Therapeutics | 1.73% |
| United States | 77.20% |
| Ireland | 1.22% |
| Bermuda | 1.13% |
| Other | 20.45% |
| Health Care | 82.16% |
| Consumer Staples | 0.02% |
| Other | 17.82% |
| YTD | +4.67% |
| 1 month | +3.06% |
| 3 months | +6.32% |
| 6 months | +26.50% |
| 1 year | +15.63% |
| 3 years | +29.60% |
| 5 years | +20.33% |
| Since inception (MAX) | +75.36% |
| 2025 | +17.44% |
| 2024 | +5.43% |
| 2023 | +0.53% |
| 2022 | -5.02% |
| Volatility 1 year | 22.96% |
| Volatility 3 years | 19.82% |
| Volatility 5 years | 22.58% |
| Return per risk 1 year | 0.68 |
| Return per risk 3 years | 0.46 |
| Return per risk 5 years | 0.17 |
| Maximum drawdown 1 year | -22.66% |
| Maximum drawdown 3 years | -25.56% |
| Maximum drawdown 5 years | -30.93% |
| Maximum drawdown since inception | -30.93% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | 2B70 | - - | - - | - |
| Stuttgart Stock Exchange | EUR | 2B70 | - - | - - | - |
| Bolsa Mexicana de Valores | MXN | - | BTEC1N MM | BTEC1N.MX | |
| London Stock Exchange | USD | BTEC | BTEC LN INAVBTEU | BTEC.L 0WXSINAV.DE | |
| London Stock Exchange | GBP | BTEK | BTEK LN INAVBTEU | BTEK.L 0WXSINAV.DE | |
| SIX Swiss Exchange | USD | BTEC | BTEC SE INAVBTEU | BTEC.S 0WXSINAV.DE | |
| XETRA | EUR | 2B70 | 2B70 GY INAVBTEE | BTEC.DE 0WXNINAV.DE |
| Nom du fonds | Taille du fonds en M € (AuM) | Frais p.a. | Distribution | Réplication |
|---|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 47 | 0,35% p.a. | Distribution | Échantillonnage |